NEW YORK (GenomeWeb News) – UK firm Epistem today announced its intention to raise £4.2 million ($6.7 million) in net proceeds in preparation of the launch of its molecular diagnostics platform and a tuberculosis assay.

The company will place 793,398 new ordinary shares of its stock at 1.5 pence each with new and existing investors. The shares have been conditionally placed at a price of 545 pence per share, a 4 percent discount to Epistem's closing price on Dec. 6, the company said.

Peel Hunt is underwriting the placement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.